## J B JOURNÉES DE L'INNOVATION EN BIOLOGIE



# Friedewald's formula and direct LDL

# assay: a comparative study

Walid Grouze<sup>1</sup>, Sana Hammami<sup>2</sup>, Brahim Khalfa<sup>2</sup>, May Selmi<sup>1</sup>, Yasmine Ghannem<sup>1</sup>, Malek Ounissi<sup>1</sup>, Rahma Mahjoub<sup>2</sup>, EmnaTalbi<sup>1</sup> 1 Clinical Biology Laboratory, Institute Of Nutrition And Food Technology – Tunis (Tunisia) 2 Ur17sp01, Clinical Biology Laboratory, Institute Of Nutrition And Food Technology – Tunis (Tunisia)

#### Contextualisation

## **Objectives**

LDL-Cholesterol (LDL-C) levels are used to define cardiovascular risk. The determination of LDL-C concentration must therefore be the most exact to assess the cardiovascular risk as accurately as possible and to adapt the treatment.


In this study, we aimed to compare LDL-C calculated (LDLc) results according to Friedewald's formula (FF) with those directly measured (LDLm).

# **Patients and Methods**

| Population distribution                    |                            | Triglycerids (TG) based distribution      |                                 |                              | Analytical method  | Statistical method   |
|--|----------------------------|---|---------------------------------|------------------------------|--|--|
| Total: 307 patients                        |                            | TG<1,13 mmol/L<br>TG=[1,13 – 2.26[ mmol/L |                                 | 141 patients<br>132 patients | <ul> <li>Biological matrix: Heparin<br/>plasma.</li> <li>Friedwald's formula:</li> </ul> | <ul> <li>Used software: SPSS</li> <li>Significance threshold:</li> <li>&lt;0,05</li> </ul>   |
| LDLm based distribution                    |                            | TG=[2,26 – 3.39[mmol/L                    |                                 | 28 patients                  |  | 10,05  |
| LDLm<1,4mmol/L                             | 5 Patients                 | TG≥3,39mmol/L                             |                                 | 6 patients                   | C-LDL (mmol/L) = C. Total - HDL - (TG/2,2)   |  |
| LDLm=[1,4-1,8[mmol/L                       | 27 Patients                | Diabetes based distribution               |                                 |                              | - LDL direct assay summarized:<br>Preliminary hydrolysis of most                         | Statistical tests  |
| LDLm=[1,8-2,6[mmol/L<br>LDLm=[2,6-3[mmol/L | 90 Patients<br>51 Patients | Diabetes                                  | Total                           | 225 patients                 | serum lipoproteins followed by<br>the double action of a                                 | <ul> <li>-Passing bablock linear regression</li> <li>- Spearman's correlation coefficient</li> <li>- Bland altman plot</li> <li>- Concordance coefficient Kappa (K)</li> </ul> |
| LDLm=[3-4,9[mmol/L                         | 122 Patients               |   | Lipids<br>lowering<br>therapy   | 152 patients                 | cholesterol oxydase/esterase<br>couple.  |  |
| LDLm≥ 4.9 mmol/L                           | 12 Patients                |   | No lipid<br>lowering<br>therapy | 72 Patients                  | - <b>Chemistry analyzer:</b> Beckman<br>Coulter <sup>®</sup> DXC 700 AU                  |  |
|  | No diabetes                |   | 82 patients                     | Counter DAC 700 A0           | -ANOVA analysis  |  |

#### **Results and discussion**





The linear correlation between LDLm and LDLc was satisfying, but better within the diabetic population (Spearman coefficient=0,98) than within the non diabetics (Spearman coefficient=0,96). The diabetic patients present however a systematic and proportional bias which is absent in the non diabetics (Figures 1: B and C). The Bland Altman plots denote a statistically significant mean difference of 0,1 mmol/L between LDLm and LDLc within the non diabetic population, the difference is however non significative for the diabetics (p=0,203) (Figure 1: D and E). Choi SY et al. also report a good correlation between LDLm and LDLc but they mention an underestimation of C-LDL using the FF [1].

The mean difference between LDLm and LDLc in the global population was **0,04 mmol/L**, **p=0,0011** (Figure 1A). There is however no global agreement on this topic in the litterature as Ghasemi et al. determined an overestimation of C-LDL by the FF while Nanda et al. concluded to a perfect correlation between LDLm and LDLc [2,3].

The linear regression revealed an underestimation of C-LDL by direct assay increasing with TG concentration.

The different Bland Altman plots show a statistically significant mean difference between LDLc of 0,03; 0,04 and 0,26 mmol/L respectively for group I,II and III. It was however non statistically significant for group IV (0,28 mmol/L), which can be caused by the low number of patients in this group (Figure 2: F,G,H and I). The correlation between LDLm and LDLc is thereafter satisfying when TG<2,26 mmol/L, these resultats are identical to those described by Nanda et al. [3].

The concordance between LDLm and LDLc and cardiovascular risk was evaluated using the Kappa coefficient. Globally, 12,4% of the results were underclassified using the FF. The concordance was better within the diabetic population ( $\kappa$ =0,754) than with non diabetics ( $\kappa$ =0,624). The diabetic patients not undergoing lipid-lowering therapy also showed a better concordance ( $\kappa$ =0,822) than the diabetic patients with lipid lowering medication ( $\kappa$ =0,725). These results are similar to those reported by Choi SY et al. [1].

#### **Conclusion and perspectives**

According to our results, diabetes associated with other factors such as triglycerides greater than 2.26 mmol/L or the presence of lipid-lowering treatment, affects FF and leads to errors in classifying patients regarding the cardiovascular risk. However, the absence of a clear consensus in the litterature prevents us from giving a clear critical point of view of the utility of the FF in the estimation of C-LDL. Nonetheless, the direct assay, although more costly, appears more efficient in the long run in determining C-LDL and precisely assessing cardiovascular risk.

#### References

| 1] Choi SY, Park HE, Kim MK, Shin CS, Cho SH, Oh BH.<br>Difference between calculated and direct-measured low-<br>density lipoprotein cholesterol in subjects with diabetes<br>mellitus or taking lipid-lowering medications J Clin |
|---|
| .ipidol 2012  |
| 2]Ghasemi A, Asgari S, Hadaegh F, Kheirandish M,  |
| Azimzadeh I, Azizi F, et al. New modified Friedewald  |
| ormulae for estimating low-density lipoprotein  |
| cholesterol according to triglyceride levels: extraction  |
| and validation. Endocr. J 2018  |
| <ol><li>Nanda SK, Bharathy M, Dinakaran A, Ray L,</li></ol>   |
| Ravichandran K. Correlation of Friedewald's calculated  |
| ow-density lipoprotein cholesterol levels with direct   |
| owdensity lipoprotein cholesterol levels in a tertiary  |
| care hospital. Int J Appl Basic Med Res 2017;   |
|   |